Artelo Biosciences, Inc. (ARTL)
| Market Cap | 3.80M +11.2% |
| Revenue (ttm) | n/a |
| Net Income | -13.47M |
| EPS | -28.02 |
| Shares Out | 3.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,220 |
| Open | 1.110 |
| Previous Close | 1.110 |
| Day's Range | 1.080 - 1.120 |
| 52-Week Range | 1.030 - 85.800 |
| Beta | -0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and inso... [Read more]
Financial Performance
Financial StatementsNews
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences presents preclinical pain data for ART26.12
Artelo Biosciences (ARTL) announced positive new data from a preclinical study in neuropathic pain from spinal cord injury. Conducted in collaboration with Stony Brook University, the study showed tha...
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain The nonclinical study conducted at Stony Brook Univ...
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26...
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOB...
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London Artelo's lead medicinal chemist reveals findings at the Royal Soci...
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences Slides: Corporate presentation
Artelo Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Artelo Biosciences Proxy statement: Proxy filing
Artelo Biosciences filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Artelo Biosciences Slides: Corporate presentation
Artelo Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalin...
Artelo Biosciences Registration statement: Registration filing
Artelo Biosciences filed a registration statement on May 14, 2026, providing details about a securities offering with the SEC.
Artelo Biosciences Quarterly report: Q1 2026
Artelo Biosciences has published its Q1 2026 quarterly earnings report on May 14, 2026.
Artelo Biosciences Earnings release: Q1 2026
Artelo Biosciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Artelo Biosciences files $75M mixed securities shelf
16:46 EDT Artelo Biosciences (ARTL) files $75M mixed securities shelf
Artelo Biosciences Registration statement: Registration filing
Artelo Biosciences filed a registration statement on May 4, 2026, providing details about a securities offering with the SEC.
Artelo Biosciences announces collaboration with ScienceMachine
Artelo Biosciences (ARTL) announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5, or FABP5, inhibitor platform...
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...
Artelo Biosciences announces publication of article on ART26.12
Artelo Biosciences (ARTL) announced the publication of a peer-reviewed article titled “Evaluating fatty acid-binding protein 5 as a therapeutic target for pain management” in the European Journal of P...
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year
Artelo Biosciences Slides: Corporate presentation
Artelo Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
Artelo Biosciences files to sell 9.82M shares of common stock for holders
16:23 EDT Artelo Biosciences (ARTL) files to sell 9.82M shares of common stock for holders
Artelo Biosciences regains compliance with Nasdaq
Artelo Biosciences (ARTL) announced that it has received a letter from Nasdaq confirming that the company has regained compliance with Nasdaq Listing Rule 5550, the “Equity Rule,” and Listing Rule…